Vaccine Asia Live: NIAID’s Effort on Dengue Vaccine R&D

Addressing Asia’s needs for vaccines in dengue, Dr Zou Lanling, Bacteriology Program Officer & Chief of Translational Sciences Section of National Institutes of Health USA, shared the efforts put into dengue vaccine R&D by National Institute of Allergy and Infectious Diseases(NIAID). NIAID conducts and supports research to develop vaccines, therapeutics and diagnostics to help understand, treat, and prevent infectious, immunologic, …

Vaccine

Vaccine Asia Live: Novel Vaccines for Emerging Diseases

Most vaccines developed target infectious diseases and cancer, with cancer vaccines being listed more under therapeutic vaccines. To enlighten us on vaccines for infectious diseases, Ms Zhang Xiaoshu, Director of Business Development at BravoBio, China, presented on the topic of Novel Vaccines for Emerging Diseases. BravoBio was founded in 2011 with its  headquarters in Shanghai and multiple sites in China. …

Round up from the World Vaccine Congress 2014

  So the World Vaccine Congress is over for its 14th year! With 80+ speakers, 40+ sponsors and over 60 sessions of scientific, corporate development and future-looking content, it was a busy few days! Opening with Dr Gregory Poland from the Mayo Clinic talking about the future of vaccinology, right from the start the focus was on what will be …

This is the Future of the Vaccine Industry

  The vaccine business is changing. The vaccine industry is moving at a remarkable pace. And we here at Vaccine Nation have sought out the the leading minds within the vaccines industry to explain the challenges and opportunities we can expect in the future. Our experts from across the vaccines spectrum explain to us the mechanics behind the vaccine industry …

Manufacturing Technology Transfer from EU to India: example JE (Japanese Encephalitis) vaccine

In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Dr. Goetz Reiner – Vice President, Bulk Manufacturing, Biological E. Limited, entitled: ‘Manufacturing Technology …

Top 20 vaccine presentation downloads for 2012

As with the previous post about the Top 5 ebooks for 2012, I thought I compile the most downloaded presentations from the last 12 months. Please allow me to take this opportunity to thank our speakers again, who very kindly take time out of their busy lives to join us at and you at the World Vaccine Congresses around the …

Opportunities given and challenges faced in the global outsourcing

Outsourcing is performed by all areas within the Pharmaceutical Industry and continues to expand. Recent survey results indicate that CMO location is relatively unimportant in comparison to establishing a good working relationship. The goals of outsourcing are universally: •    Speed•    Efficiency•    Cost effectiveness The key to all outsourcing is communication. Terry Higgins, Executive Director, Profectus Biosciences Inc joined us at …

Vaccine manufacturing facilities – best practice and new benchmarks

Vaccine manufacturing facilities facilitate the vaccine commercialization timeline, which spans from phase 1 trials to the launch. The challenges include: speed to market, large at launch capacity, representative commercial facility needed and the need to defer early investment to reduce sunk cost. The opportunities often outweigh the challenges: for example, multi-use facilities and modular design. MedImmune Strategy to meet these …

What are the new regulatory considerations for vaccine manufacturing?

Vaccine manufacturing is at the heart of the vaccine industry. Jane Halpern, Vice President, Regulatory Affairs, Novavax joined us at the World Vaccine Congress 2012 in Washington to detail the new regulatory considerations for vaccine manufacturing. Novavax is developing a series of recombinant vaccines for infectious diseases using its recombinant nanoparticle platform, a Virus-like particle (VLP) vaccine (influenza) with Nanoparticle …

Meeting the manufacturing challenges for dengue vaccine demand in endemic and non-endemic

Joe Santangelo, COO, Inviragen Inc. Joined us at the World Vaccine Congress 2012 in Washington to give details on Inviragen's current vaccine pipeline. The current focus for the company is the development of vaccines for infectious diseases with a focus on emerging economies. With international operations with offices in Colorado, Wisconsin and Singapore, the vaccine pipeline currently has four key …